Humira Biosimilar: Boehringer Faces Same Launch Hurdles As Amgen
Executive Summary
AbbVie seeks injunction against Boehringer Ingelheim's Cyltezo claiming infringement of 74 patents, 8 of which are in the initial round of litigation; as of Aug. 2, BI had not given 180-day launch notice.
You may also be interested in...
Does AbbVie Have 'Unclean Hands' From Building Humira Patent Thicket? Judge Allows Discovery
Magistrate judge says Boehringer's theory 'may or may not be viable' as an infringement defense; permits third party subpoenas for information on clinical trials.
Does AbbVie Have 'Unclean Hands' From Building Humira Patent Thicket? Judge Allows Discovery
Magistrate judge says Boehringer's theory 'may or may not be viable' as an infringement defense; permits third party subpoenas for information on clinical trials.
Humira's 'Unique' Number Of Patents Makes Biosimilar Entry Risky, Pfizer Says
Pfizer wants to get its adalimumab biosimilar to market as soon as possible, but won’t say whether that’s before AbbVie's patents run out in 2023.